|
A clinical study on the role of Akshi Tarpana with Jeevantyadi Ghrita in Timira (Myopia)
Poonam1, R Manjusha2, DB Vaghela3, VJ Shukla4
1 Lecturer, Department of Shalakya Tantra, Pankaj Kasturi Ayurveda Medical College, Trivendrum, Kerala, India
2 Associate Professor, Department of Shalakya Tantra, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
3 Assistant Professor, Department of Shalakya Tantra, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
4 Head, Pharmaceutical Chemistry Laboratory, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
Correspondence Address:
Poonam
247, Dayanand Colony, Model Town, Karnal, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-8520.96130
|
|
Myopia is a major public health problem pertaining to eye that entails substantial societal, personal, educational, and economical impact. Various surveys in India have found the prevalence of myopia ranging from 6.9% to 19.7%. Myopia progression is irreversible and methods for the correction of myopia are not without complications. Myopia closely resembles Timira involving first and second Patala in terms of symptoms, anatomical structures involved, and the pathogenesis of the disease. The study is aimed at evaluating the efficacy of the Akshi-Tarpana procedure with Jeevantyadi Ghrita in fresh and old myopes. A total of 54 patients (108 eyes) having myopia ≥-6 D were registered for the study and divided into two groups (Group A, Akshi-Tarpana with Jeevantyadi Ghrita, and Group B, Akshi-Tarpana with plain Go Ghrita), by stratified sampling. The procedure was done in 5 sittings of 5 days each with an equal interval of 5 days between each sitting. A total of 22 patients in Group A and 18 in Group B completed the treatment. Obtained data were statistically analyzed using a t-test and the study reveals that objectively, 09.30% and 05.55% eyes were cured, 16.28% and 02.78% markedly improved, and 34.88% and 11.11% moderately improved in Group A and B, respectively. |
